A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Nov 18, 2026; every other figure is from the SEC filings on this page. Not financial advice.
Newest figures come from the 10-Q for Q3 FY2026, filed Nov 9, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the ZNTL SEC filings page.
Zentalis Pharmaceuticals, Inc. (ZNTL) reported $0 in revenue for fiscal year 2025, down 100.0% from the prior fiscal year. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 7 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Zentalis remains a development-stage business: FY2024 research spending exceeded revenue, while operating cash flow closely tracked its net loss.
In FY2024, the net loss of$165.8M and operating cash flow of-$170.9M were close, while free cash flow was-$171.1M despite only$221K of capital expenditures. That combination indicates cash use was principally operating development spending, not heavy physical investment.
The expense structure is development-led: research and development consumed
A 7.3x current ratio and liabilities equal to
Financial Health Signals
We do not publish a peer-relative financial health score for Zentalis Pharmaceuticals, Inc., because the score only covers companies whose filings and listing give us what it needs to compare them with their peers. The signals and metrics below are current.
Zentalis Pharmaceuticals, Inc. scores -5.52, below the 1.81 distress threshold. The score is pulled down most by an accumulated deficit of $1.2B against total assets of $289.0M. This indicates elevated financial distress risk and warrants close attention to liquidity and debt levels.
Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.
Zentalis Pharmaceuticals, Inc. passes 2 of 7 computable financial strength tests (2 of the nine could not be computed from available data). 1 of 4 profitability signals pass, 1 of 2 leverage/liquidity signals pass, the one computable operating efficiency signal (asset turnover improving) does not pass.
Zentalis Pharmaceuticals, Inc. reported a net loss of $137.1M while operations used $125.2M of cash. With neither figure positive, the ratio between the two carries no quality signal.
Key Financial Metrics
Earnings & Revenue
Zentalis Pharmaceuticals, Inc.'s EBITDA was -$31.0M in Q3 2026, measuring earnings before interest, taxes, depreciation, and amortization. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.
Zentalis Pharmaceuticals, Inc. reported a net loss of $28.8M in Q3 2026. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.
Zentalis Pharmaceuticals, Inc. earned -$0.34 per diluted share (EPS) in Q3 2026. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.
Not reported for Q3 2026.
Cash & Balance Sheet
Zentalis Pharmaceuticals, Inc. recorded an outflow of $32.7M in free cash flow in Q3 2026, representing a cash shortfall after capex. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.
Zentalis Pharmaceuticals, Inc. held $24.0M in cash as of Q3 2026; no long-term debt figure is on record for that period.
Not reported for Q3 2026.
Margins & Returns
Zentalis Pharmaceuticals, Inc.'s quarterly ROE was -14.1% in Q3 2026: one quarter's net income over shareholder equity, not annualized. This is down 3.5 percentage points from the same quarter a year earlier. Against the prior quarter it is up 15.4 percentage points.
Not reported for Q3 2026.
Not reported for Q3 2026.
Not reported for Q3 2026.
Capital Allocation
Zentalis Pharmaceuticals, Inc. invested $22.3M in research and development in Q3 2026. This represents a decrease of 2.7% from the same quarter a year earlier. Against the prior quarter it is down 36.5%.
Zentalis Pharmaceuticals, Inc. reported no capital expenditure in Q3 2026. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.
Not reported for Q3 2026.
ZNTL Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q3'2610-Q | Q2'2610-Q | Q1'2610-Q | Q4'2510-K | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K |
|---|---|---|---|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | $0-100.0% | $0n/m | $0n/m | $0-100.0% | $26.9Mn/m |
| R&D Expenses | $22.3M-2.7% | $35.2M+27.4% | $28.7M+5.4% | $29.5M-10.6% | $22.9M-37.7% | $27.6M-42.9% | $27.2M-45.0% | $33.0M-36.0% |
| SG&A Expenses | $8.8M-18.2% | $9.2M+9.2% | $9.1M-13.6% | $7.9M-80.2% | $10.8M-26.2% | $8.4M-49.6% | $10.6M-32.8% | $40.0M+144.5% |
| Operating Income | -$31.2Mn/m | -$44.4Mn/m | -$37.9Mn/m | -$37.4Mn/m | -$33.7Mn/m | -$36.1Mn/m | -$45.6Mn/m | -$49.8Mn/m |
| EBITDA | -$31.0Mn/m | -$44.2Mn/m | -$37.7Mn/m | N/A | -$33.6Mn/m | -$35.9Mn/m | -$45.4Mn/m | N/A |
| Income Tax | $118Kn/m | $138Kn/m | $120Kn/m | $442Kn/m | $0n/m | $0-100.0% | $0-100.0% | -$205Kn/m |
| Net Income | -$28.8Mn/m | -$42.3Mn/m | -$35.4Mn/m | -$35.2Mn/m | -$26.7Mn/m | -$26.9Mn/m | -$48.3M-579.5% | -$47.5Mn/m |
| EPS (Basic) | -$0.34n/m | -$0.59n/m | -$0.50n/m | -$0.49n/m | -$0.37n/m | -$0.37n/m | -$0.67-578.6% | -$0.66n/m |
| EPS (Diluted) | -$0.34n/m | -$0.59n/m | -$0.50n/m | -$0.49n/m | -$0.37n/m | -$0.37n/m | -$0.67-578.6% | -$0.66n/m |
| Diluted Shares (Avg) | 85M+17.3% | 71M-0.9% | 70M-2.0% | N/A | 72M+1.4% | 72M+1.3% | 72M+0.7% | N/A |
Not reported in any period shown, so not listed: Cost of Revenue, Gross Profit, Interest Expense.
ZNTL Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q3'2610-Q | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $270.2M-17.4% | $215.3M-38.8% | $253.1M-34.1% | $289.0M-32.9% | $327.3M-27.4% | $351.7M-28.5% | $384.0M-31.1% | $430.3M-22.0% |
| Current Assets | $237.3M-17.7% | $181.3M-41.8% | $218.1M-36.4% | $253.2M-34.4% | $288.3M-28.0% | $311.6M-29.1% | $342.9M-31.9% | $386.1M-22.3% |
| Cash & Equivalents | $24.0M-38.5% | $24.8M-34.1% | $31.9M-23.8% | $36.0M+6.2% | $39.1M-5.4% | $37.6M+1.7% | $41.9M+11.5% | $33.9M+20.9% |
| Short-Term Investments | $204.9M-14.4% | $149.8M-39.8% | $179.8M-35.4% | $209.9M-34.0% | $239.2Mn/m | $249.0M | $278.4M | $318.0M-30.1% |
| Accounts Receivable | N/A | N/A | N/A | $0-100.0% | $0 | $0 | $0 | $5.0Mn/m |
| Long-Term Investments | $0 | $0 | $0 | N/A | N/A | N/A | N/A | N/A |
| Goodwill | N/A | N/A | N/A | N/A | N/A | N/A | N/A | $0-100.0% |
| Total Liabilities | $65.3M-12.2% | $71.7M-7.2% | $70.4M-20.6% | $72.8M-21.9% | $74.4M-22.8% | $77.2M-29.2% | $88.6M-10.2% | $93.2M-18.5% |
| Current Liabilities | $32.4M-12.9% | $37.6M-3.6% | $35.2M-28.7% | $36.6M-30.7% | $37.2M-32.3% | $39.0M-41.5% | $49.4M-9.8% | $52.7M-24.0% |
| Non-Current Liabilities | $32.9M-11.5% | $34.1M-10.8% | $35.1M-10.4% | $36.2M-10.4% | $37.2M-10.2% | $38.2M-9.9% | $39.2M-10.7% | $40.4M-10.0% |
| Total Equity | $204.9M-19.0% | $143.6M-47.7% | $182.7M-38.2% | $216.2M-35.9% | $252.9M-28.6% | $274.5M-28.3% | $295.4M-35.6% | $337.2M-22.9% |
| Retained Earnings | -$1.3Bn/m | -$1.3Bn/m | -$1.2Bn/m | -$1.2Bn/m | -$1.2Bn/m | -$1.1Bn/m | -$1.1Bn/m | -$1.1Bn/m |
Not reported in any period shown, so not listed: Inventory, Long-Term Debt.
ZNTL Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q3'2610-Q | Q2'2610-Q | Q1'2610-Q | Q4'2510-K | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$32.7Mn/m | -$37.2Mn/m | -$33.0Mn/m | -$30.9Mn/m | -$27.0Mn/m | -$34.7Mn/m | -$32.6Mn/m | -$39.7Mn/m |
| Depreciation & Amortization | $152K-5.0% | $152K-5.0% | $151K-42.4% | $157K-50.5% | $160K-50.2% | $160K-51.1% | $262K-19.1% | $317K-5.9% |
| Stock-Based Compensation | $3.2M-33.4% | $3.2M-48.9% | $3.2M-50.7% | N/A | $4.8M-53.4% | $6.3M-50.5% | $6.5M-49.5% | N/A |
| Capital Expenditures | $0n/m | $0n/m | $34Kn/m | $0n/m | $0n/m | $0-100.0% | $0-100.0% | $0-100.0% |
| Free Cash Flow | -$32.7Mn/m | -$37.2Mn/m | -$33.0Mn/m | -$30.9Mn/m | -$27.0Mn/m | -$34.7Mn/m | -$32.6Mn/m | -$39.7Mn/m |
| Investing Cash Flow | -$55.3M-295.3% | $30.0M-1.2% | $30.0M-25.8% | $32.4M+0.5% | $28.3M-41.3% | $30.4M-11.9% | $40.5M-34.2% | $32.3Mn/m |
| Financing Cash Flow | $87.3M+75777.4% | $65Kn/m | -$1.1M-694.2% | -$4.6Mn/m | $115K+25.0% | $0-100.0% | $189K+2600.0% | $0n/m |
Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.
ZNTL Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q3'2610-Q | Q2'2610-Q | Q1'2610-Q | Q4'2510-K | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K |
|---|---|---|---|---|---|---|---|---|
| Operating Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | -185.5% |
| Net Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | -176.7% |
| Return on Equity | -14.1%-3.5pp | -29.4%-19.7pp | -19.4%-3.0pp | -16.3%-2.2pp | -10.6%+0.8pp | -9.8%+13.3pp | -16.3%-18.5pp | -14.1%-0.1pp |
| Return on Assets | -10.7%-2.5pp | -19.6%-12.0pp | -14.0%-1.4pp | -12.2%-1.2pp | -8.2%+0.7pp | -7.6%+10.3pp | -12.6%-14.4pp | -11.0%0.0pp |
| Current Ratio | 7.33-0.4x | 4.82-3.2x | 6.19-0.7x | 6.93-0.4x | 7.76+0.5x | 7.99+1.4x | 6.94-2.3x | 7.32+0.2x |
| Liabilities-to-Equity | 0.320.0x | 0.50+0.2x | 0.39+0.1x | 0.34+0.1x | 0.290.0x | 0.280.0x | 0.30+0.1x | 0.280.0x |
| Asset Turnover | N/A | N/A | N/A | 0.00-0.1x | 0.000.0x | 0.000.0x | 0.00-0.1x | 0.06+0.1x |
| FCF Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | -147.8% |
Not reported in any period shown, so not listed: Gross Margin, Debt-to-Equity.
Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Operating Margin, Net Margin, FCF Margin.
Similar Companies
Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it. Market cap is stated at each company's latest close.
| Company | Fiscal year | Revenue | Net income | Net margin | Market cap | Health score |
|---|---|---|---|---|---|---|
| Zentalis Pharmaceuticals, Inc. ZNTL | FY2025 | $0 | -$137.1M | N/A | $133.6M | — |
| BridgeBio Oncology Therapeutics, Inc. BBOT | FY2025 | N/A | -$134.0M | N/A | $144.9M | — |
| Fate Therapeutics, Inc. FATE | FY2025 | $6.6M | -$136.3M | N/A | $127.8M | 56/100 |
| InflaRx N.V. IFRX | FY2025 | $34K | -$53.6M | N/A | $163.6M | — |
| enGene Therapeutics Inc. ENGN | FY2025 | N/A | -$117.3M | N/A | $124.0M | — |
| ALX Oncology Holdings Inc. ALXO | FY2025 | N/A | -$101.7M | N/A | $134.1M | — |
Where Zentalis Pharmaceuticals, Inc. Ranks
Frequently Asked Questions
Zentalis Pharmaceuticals, Inc. (ZNTL) reported $0 in total revenue for fiscal year 2025. This represents a -100.0% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
Zentalis Pharmaceuticals, Inc. (ZNTL) revenue declined by 100.0% year-over-year, from $67.4M to $0 in fiscal year 2025.
No, Zentalis Pharmaceuticals, Inc. (ZNTL) reported a net loss of $137.1M in fiscal year 2025.
Zentalis Pharmaceuticals, Inc. (ZNTL) had EBITDA of -$152.1M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
Zentalis Pharmaceuticals, Inc. (ZNTL) has a return on equity of -63.4% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
Zentalis Pharmaceuticals, Inc. (ZNTL) recorded an outflow of $125.2M in free cash flow during fiscal year 2025. The change from the previous fiscal year is not meaningful, because that year’s figure was zero or negative. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
Zentalis Pharmaceuticals, Inc. (ZNTL) recorded an outflow of $125.2M in operating cash flow during fiscal year 2025, representing cash used by core business activities.
Zentalis Pharmaceuticals, Inc. (ZNTL) had $289.0M in total assets as of fiscal year 2025, including both current and long-term assets.
Zentalis Pharmaceuticals, Inc. (ZNTL) reported no capital expenditure during fiscal year 2025.
Zentalis Pharmaceuticals, Inc. (ZNTL) invested $107.3M in research and development during fiscal year 2025.
Zentalis Pharmaceuticals, Inc. (ZNTL) had a current ratio of 6.93 as of fiscal year 2025, which is generally considered healthy.
Zentalis Pharmaceuticals, Inc. (ZNTL) had a liabilities-to-equity ratio of 0.34 as of fiscal year 2025, which is total liabilities divided by total shareholder equity. Total liabilities counts every obligation on the balance sheet (payables, deposits, insurance reserves and deferred taxes as well as borrowings), so this ratio usually runs well above debt-to-equity. No debt-to-equity ratio is shown for fiscal year 2025, because the filing data we hold for that year carries no long-term debt figure.
Zentalis Pharmaceuticals, Inc. (ZNTL) had a return on assets of -47.4% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
Zentalis Pharmaceuticals, Inc. (ZNTL) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (trailing 12 months to September 30, 2026). The market capitalization is $133.6M as of Nov 18, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
Zentalis Pharmaceuticals, Inc. (ZNTL) has no price-to-sales ratio at the moment: revenue is not positive (FY2025). The market capitalization is $133.6M as of Nov 18, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
Zentalis Pharmaceuticals, Inc. (ZNTL) has an Altman Z-Score of -5.52, placing it in the Distress Zone (elevated bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
Zentalis Pharmaceuticals, Inc. (ZNTL) has a Piotroski F-Score of 2 out of 7 computable signals; 2 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Zentalis Pharmaceuticals, Inc. (ZNTL) reported a net loss of $137.1M while operations used $125.2M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.